Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation (SBIR) (R44 Clinical Trial Not Allowed)

The summary for the Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation (SBIR) (R44 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation (SBIR) (R44 Clinical Trial Not Allowed): Human induced pluripotent stem cells (iPSCs) have been used with great success to mimic the differentiation of a variety of tissues, understand early development and study human diseases. Despite approaches that have made the derivation, growth and differentiation of iPSCs more efficient, there remains significant variability in reprogramming efficacy, genomic integrity and developmental potential of iPSCs derived from a single fibroblast or tissue sample. Thus, iPSCs derived from the same sample may differ in their in vitro growth characteristics and their ability to re-differentiate into the desired tissue type. A variety of issues may affect derivation of the iPSCs and their growth, stability and differentiation, including the specific characteristics of the starting cell or tissue sample (e.g., age of donor, tissue type and anatomical location, physiological and disease state), the methods and protocols used to induce pluripotency (e.g., transcription factors, small molecules, cell fusion), the choice of growth factors and other culture conditions, method of storage of cell lines, etc. Further challenges include growing and maintaining sufficient quantities of iPSC lines in culture without changes in their properties, as well as the ability of multiple investigators to identify and authenticate iPSC lines as part of their research. This Funding Opportunity Announcement (FOA) will support SBIR projects to develop novel, reliable and cost-effective methods to standardize and increase the utility and reproducibility of iPSCs at all stages, from their derivation to their research and clinical applications.
Federal Grant Title: Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation (SBIR) (R44 Clinical Trial Not Allowed)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education Environment Food and Nutrition Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-GM-19-001
Type of Funding: Grant
CFDA Numbers: 93.113, 93.121, 93.233, 93.273, 93.279, 93.286, 93.350, 93.393, 93.394, 93.395, 93.396, 93.399, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.855, 93.859
CFDA Descriptions: Information not provided
Current Application Deadline: January 6th, 2020
Original Application Deadline: January 6th, 2020
Posted Date: May 21st, 2019
Creation Date: May 21st, 2019
Archive Date: February 11th, 2020
Total Program Funding:
Maximum Federal Grant Award: $375,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: May 21st, 2019
Applicants Eligible for this Grant
Small businesses
Additional Information on Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement
Grant Announcement Contact
NIH OER Webmaster
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
More Grants from the National Institutes of Health
Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan... is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2020